Positive Free Cash Flow Stocks in Health Care
Companies generating positive free cash flow, indicating they produce more cash than they invest in capital expenditures.
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
66 Companies Meeting Criteria
Showing 1–50 of 66 companies, ranked by Free Cash Flow.
| # | Company | Free Cash Flow | FCF Margin |
|---|---|---|---|
| 1 | JNJJohnson & Johnson | $19.7B | 20.9% |
| 2 | ABBVAbbVie | $17.8B | 29.1% |
| 3 | BMYBristol Myers Squibb | $12.8B | 26.7% |
| 4 | MRKMerck & Co. | $12.4B | 19.0% |
| 5 | GILDGilead Sciences | $9.5B | 32.1% |
| 6 | PFEPfizer | $9.1B | 14.5% |
| 7 | AMGNAmgen | $8.1B | 22.0% |
| 8 | REGNRegeneron Pharmaceuticals | $4.1B | 28.4% |
| 9 | VRTXVertex Pharmaceuticals | $3.2B | 26.6% |
| 10 | ZTSZoetis | $2.3B | 24.1% |
| 11 | BIIBBiogen | $2.1B | 20.7% |
| 12 | VTRSViatris | $1.9B | 13.6% |
| 13 | JAZZJazz Pharmaceuticals | $1.3B | 30.4% |
| 14 | TEVATEVA PHARMACEUTICAL INDUSTRIES LTD | $1.1B | 6.7% |
| 15 | UTHRUnited Therapeutics | $1.0B | 32.7% |
| 16 | BHCBausch Health Companies Inc. | $1.0B | 9.8% |
| 17 | ONCBeOne Medicines Ltd. | $942M | 17.6% |
| 18 | EXELExelixis | $876M | 37.8% |
| 19 | NBIXNeurocrine Biosciences | $749M | 26.2% |
| 20 | BMRNBioMarin Pharmaceutical | $725M | 22.5% |
| 21 | PTCTPTC Therapeutics, Inc. | $702M | 40.6% |
| 22 | HALOHalozyme | $645M | 46.2% |
| 23 | OGNOrganon & Co. | $538M | 8.7% |
| 24 | ALKSAlkermes plc | $480M | 32.6% |
| 25 | ALNYALNYLAM PHARMACEUTICALS, INC. | $465M | 12.5% |
| 26 | HRMYHarmony Biosciences Holdings, Inc. | $348M | 40.1% |
| 27 | BCRXBIOCRYST PHARMACEUTICALS INC | $345M | -37.8% |
| 28 | COLLCollegium Pharmaceutical, Inc. | $328M | 42.0% |
| 29 | INCYIncyte | $287M | 6.8% |
| 30 | ELANElanco | $284M | 6.0% |
| 31 | AMRXAmneal Pharmaceuticals, Inc. | $270M | 8.9% |
| 32 | PBHPrestige Consumer Healthcare | $239M | 21.3% |
| 33 | TBPHTheravance Biopharma, Inc. | $238M | -18.4% |
| 34 | CPRXCatalyst Pharmaceuticals Partners, Inc. | $209M | 35.4% |
| 35 | INVAInnoviva, Inc. | $196M | 47.6% |
| 36 | KRYSKrystal Biotech, Inc. | $189M | 48.5% |
| 37 | ANIPANI Pharmaceuticals, Inc. | $171M | 19.4% |
| 38 | ARWRArrowhead Pharmaceuticals | $157M | 18.9% |
| 39 | EBSEmergent BioSolutions Inc. | $157M | 21.1% |
| 40 | PRGOPerrigo | $145M | 3.4% |
| 41 | CORTCorcept Therapeutics Incorporated | $142M | 18.6% |
| 42 | PCRXPacira BioSciences, Inc. | $137M | 18.8% |
| 43 | KNSAKiniksa Pharmaceuticals International, plc | $136M | 20.1% |
| 44 | IRWDIRONWOOD PHARMACEUTICALS INC | $127M | 42.9% |
| 45 | AMPHAmphstar Pharmaceuticals, Inc. | $121M | 16.8% |
| 46 | SEPNSepterna, Inc. | $110M | - |
| 47 | ACADAcadia Pharmaceuticals | $105M | 9.8% |
| 48 | RGENRepligen | $94M | 39.2% |
| 49 | FTREFortrea | $88M | 3.2% |
| 50 | DVAXDynavax Technologies Corp. | $60M | 21.7% |
Understanding Free Cash Flow
Free cash flow (FCF) is the cash remaining after a company pays operating expenses and capital expenditures. Positive FCF means the company generates real cash that can be used for dividends, share buybacks, acquisitions, or debt reduction. Many investors consider FCF more reliable than net income because it is harder to manipulate.
FCF > $0
Results are based on SEC EDGAR filings. Companies with missing, unreliable, or extreme outlier values are excluded from screening.
Related Rankings
See the top companies ranked by these related metrics